Fibrinogen Aα312 and Bβ448 polymorphisms are not related to bleeding during oral vitamin K-antagonist treatment

• References

• 1 Scott EM, Ariëns RAS, Grant PE. Genetic and environmental determinants of fibrin structure and function: relevance to clinical disease. Arterioscler Thromb Vasc Biol 2004; 24: 1558-1566.
• 2 Standeven KF, Ariëns RAS, Grant PE. The molecular physiology and pathology of fibrin structure/function. Blood Rev 2005; 19: 275-288.
• 3 Maghzal GJ, Brennan SO, George PM. Fibrinogen B beta polymorphisms do not directly contribute to an altered in vitro clot structure in humans. Thromb Haemost 2003; 90: 1021-1028.
• 4 Carter AM, Catto AJ, Grant PJ. Association of the alpha-fibrinogen Thr312Ala polymorphism with poststroke mortality in subjects with atrial fibrillation. Circulation 1999; 99: 2423-2426.
• 5 Standeven KF, Grant PJ, Carter AM. et al. Functional analysis of the fibrinogen Aalpha Thr312Ala polymorphism: effects on fibrin structure and function. Circulation 2003; 107: 2326-2330.
• 6 Lim BC, Ariens RA, Carter AM. et al. Genetic regulation of fibrin structure and function: complex gene-environment interactions may modulate vascular risk. Lancet 2003; 361: 1424-1431.
• 7 Reitsma PH, van der Heijden JF, Groot AP. et al. A C1173T Dimorphism in the VKORC1 Gene Determines Coumarin Sensitivity and Bleeding Risk. PLoS Med 2005; 2: e312
• 8 van der Heijden JF, Rekke B, Hutten BA. et al. Nonfatal major bleeding during treatment with vitamin K antagonists: influence of soluble thrombomodulin and mutations in the propeptide of coagulation factor IX. J Thromb Haemost 2004; 2: 1104-1109.
• 9 Schneider S, Roessli D, Excoffier L. Arlequin: a software for population genetics data analysis. User manual ver 2.000. Ver. 2.000. Geneva: Genetics and Biometry Lab, Dept. of Anthropology, University of Geneva.